AbbVie announced positive topline results from a Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog licensed from Gubra for $350M upfront in March 2025125.
Weekly dosing cohorts showed average weight loss of 7.7%, 8.7%, and 9.8% at 12 weeks, with a favorable tolerability profile and mostly mild GI adverse events15.
Gubra's CEO expressed encouragement, noting dose-dependent weight loss and potential for ABBV-295 in obesity treatment26.
Analysts view the ~10% weight loss as competitive in the amylin class, predicting Phase 2 start later in 202614.
No search results confirm recent success of a Regeneron obesity drug in China.
Sources:
1. https://www.fiercebiotech.com/biotech/abbvie-ties-350m-obesity-bet-almost-10-weight-loss-after-12-weeks
2. https://www.tradingview.com/news/modular_finance:2fbfae11b2ae4:0-abbvie-reports-positive-phase-1-multiple-ascending-dose-results-for-abbv-295-a-long-acting-amylin-analog/
4. https://www.inderes.dk/en/analyst-comments/gubra-fy2025-clinical-progress-the-focus-in-2026-after-record-year-with-abbvie-partnership
5. https://news.abbvie.com/2026-03-09-AbbVie-Announces-Positive-Topline-Results-from-a-Phase-1-Multiple-Ascending-Dose-Study-of-ABBV-295,-a-Long-Acting-Amylin-Analog,-in-Adults
6. https://www.gubra.dk/mfn_news/abbvie-reports-positive-phase-1-multiple-ascending-dose-results-for-abbv-295-a-long-acting-amylin-analog/